Spago Nanomedical AB

More Accurate Diagnosis and Treatments

The company's operations are based on a patented material for the design of functional nanoparticles that accumulate physilogically in tumors, thus enabling higher precision and improved patient care. The current pipeline projects have the potential to facilitate diagnostics and improve the treatment of indications with urgent medical needs.

TheSpagoPixproject aims to launch a ground-breaking gadolinium-free MRI contrast agent for visualization of tumors and metastases. Unlike the conventional low molecular-weight MRI contrast agents, which enhance healthy tissue as well as tumor tissue, and therefore results in a relatively high proportion of false positive findings, Spago Nanomedical’s proprietary contrast agent is designed to selectively accumulate in tumor tissue. This improves the precision of MRI scans for suspected cancers. With better cancer diagnostics, the chances of successful and cost-efficient treatment of cancer patients improve. TheTumorad®project aims to develop a novel therapeutic radiopharmaceutical targeting solid tumors based on nanoparticles loaded with radioactive isotopes. The design of Tumorad® makes tumor selectivity possible even in the case of small, difficult-to-reach and aggressive tumors, which enables efficient radiation treatment of the cancer while minimizing the risk of adverse effects.